Diaceutics (LON:DXRX) Reaches New 52-Week High – Should You Buy?

Diaceutics PLC (LON:DXRX)’s stock price reached a new 52-week high during mid-day trading on Monday. The company traded as high as GBX 210 and last traded at GBX 206.50, with a volume of 227,890 shares changing hands. The stock had previously closed at GBX 203.52.

Analyst Ratings Changes

Separately, Canaccord Genuity Group reiterated a “buy” rating and issued a GBX 215 target price on shares of Diaceutics in a report on Tuesday, September 22nd. Two investment analysts have rated the stock with a Buy rating. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of GBX 215.

Diaceutics Stock Up 1.5%

The company has a debt-to-equity ratio of 5.40, a current ratio of 2.55 and a quick ratio of 9.92. The business has a 50 day moving average price of GBX 168.39 and a 200 day moving average price of GBX 157.80. The firm has a market capitalization of £175.30 million, a P/E ratio of -645.31 and a beta of 0.88.

Diaceutics (LON:DXRX) last posted its quarterly earnings data on Tuesday, September 22nd. The company reported GBX (3.27) earnings per share for the quarter. Diaceutics had a negative return on equity of 0.68% and a negative net margin of 0.66%. On average, analysts predict that Diaceutics PLC will post 1.01 earnings per share for the current year.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.